Bristol-Myers Squibb Co (BMY) is WealthTrust Axiom LLC’s 2nd Largest Position

WealthTrust Axiom LLC lessened its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,209 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the quarter. Bristol-Myers Squibb comprises 3.1% of WealthTrust Axiom LLC’s portfolio, making the stock its 2nd biggest holding. WealthTrust Axiom LLC’s holdings in Bristol-Myers Squibb were worth $8,108,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Segantii Capital Management Ltd acquired a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at about $544,000. Columbia Asset Management increased its stake in Bristol-Myers Squibb by 4.1% during the 1st quarter. Columbia Asset Management now owns 16,574 shares of the biopharmaceutical company’s stock worth $901,000 after buying an additional 650 shares in the last quarter. Legal & General Group Plc lifted its stake in Bristol-Myers Squibb by 4.3% during the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after purchasing an additional 335,795 shares in the last quarter. State Street Corp lifted its stake in Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares in the last quarter. Finally, New England Asset Management Inc. raised its stake in shares of Bristol-Myers Squibb by 22.2% in the first quarter. New England Asset Management Inc. now owns 42,900 shares of the biopharmaceutical company’s stock valued at $2,333,000 after acquiring an additional 7,800 shares in the last quarter. 69.67% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.

BMY has been the subject of several recent analyst reports. Barclays lifted their target price on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research note on Friday, October 13th. Jefferies Group lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price on the stock. in a report on Monday, October 16th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 12th. Leerink Swann lifted their target price on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Finally, Citigroup boosted their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $65.05.

Bristol-Myers Squibb Co (BMY) traded up $0.34 during trading hours on Friday, hitting $62.81. 5,489,081 shares of the stock were exchanged, compared to its average volume of 5,400,000. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $66.10. The company has a market cap of $102,800.00, a P/E ratio of 24.73, a price-to-earnings-growth ratio of 2.29 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.77 earnings per share. equities research analysts predict that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. Bristol-Myers Squibb’s payout ratio is currently 62.99%.

COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/bristol-myers-squibb-co-bmy-position-trimmed-by-wealthtrust-axiom-llc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply